There are very few companies in the biotech space which have managed to make the sort of innovative step forward like ImmunoPrecise Antibodies Ltd (NASDAQ:IPA) has managed to and that is perhaps one of the reasons why it is a company that could be tracked by investors at this point.
As it happens, the stock was in focus yesterday as it ended up with gains of as much as 7.43% with trading volumes soaring past the average 60-day volume. In this regard, it ought to be noted that the company has managed to come up with a revolutionary new technology powered by artificial intelligence that could make it a major player in the long run in the pharmaceutical and biotech industries.
The technology that the company has come up with is called LENS, which is powered by artificial intelligence and uses the HYFT index. The platform is meant for analyzing and reading complex biological data in a thorough manner which cannot be replicated by any other algorithm at this point. It provides differentiated outputs with actionable insights into the data which cannot be provided by any other algorithm. More importantly, it provides analysis of data in a thorough manner with a lot less time than other algorithms.
In addition to that, it is also necessary to point out that the LENS platform from ImmunoPrecise Antibodies has considerable commercial implications as well. In the coming years, there are going to be a number of big-ticket acquisitions in this field as giants like Google, Facebook, and Microsoft look to acquire revolutionary technology.
That may place ImmunoPrecise Antibodies in an enviable position with its revolutionary technology and platform. Additionally, it is the sort of technology that can also be deployed in other industries which may need such analyses.